Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

NCT04900623 is registered in ClinicalTrials.gov with Jonathan Schoenfeld, MD, MPH as lead sponsor.

NCT NCT04900623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04900623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Lead sponsor
Jonathan Schoenfeld, MD, MPH
Phase
Phase 2
Overall status
Recruiting
Start date
July 2, 2021
Completion date
June 1, 2032
Enrollment
145 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, hpv positive oropharyngeal squamous cell carcinoma, hpv-associated oropharyngeal squamous cell carcinoma, hpv-mediated (p16-positive) oropharyngeal carcinoma by ajcc v8 clinical stage, hpv-mediated (p16-positive) oropharyngeal carcinoma by ajcc v8 pathologic stage, hpv-mediated (p16-positive) oropharyngeal carcinoma by ajcc v8 stage, hpv-related squamous cell carcinoma, pathologic stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, pathologic stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, pathologic stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8